How To Win The Biosimilars Race In The European Union Onco-Therapeutics Market in 2020?

The healthcare market has been growing for biosimilars in the European Union (EU), however, the rosy picture is expected to change as the long term sustainability of the pharmaceutical market is expected to come under lens due to shortage of big biologic patent expiries.

The entry of Chinese and Singaporean drug manufacturers causes a slight change of focus to the Russian and Central Europe region and also because of a growing number of new innovative drugs targeted at focused patient groups.

Download this Whitepaper, based on a study conducted by SG Analytics to know more.

Download ?>

Get all of our articles and insights as soon as they're published.

DOWNLOAD WHITEPAPER



*By sharing the information you have entered, you give your express consent to SG Analytics to use the provided information to contact you with relevant information related to its offerings and services as and when required. SG Analytics secures all your personal information from unauthorized access, use or disclosure. For more information, please visit our privacy policy.

DOWNLOAD Case Study



*By sharing the information you have entered, you give your express consent to SG Analytics to use the provided information to contact you with relevant information related to its offerings and services as and when required. SG Analytics secures all your personal information from unauthorized access, use or disclosure. For more information, please visit our privacy policy.

GDPA
ISOISO